RxDoctor Payments Data

Alan Abramowitz, DO

Internal Medicine · Fountainville, PANPI 1730181595

Payments from drug & device makers

$326in general payments, 2019–2025

Across 17 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$72
  • Abbott$45
  • Pfizer$43
  • Novo Nordisk$37
  • Amgen$33
  • Sanofi Pasteur Inc.$24
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$326 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$246,185
Medicare patients
549
Services billed
2,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept24$188,504
EliquisApixaban873$172,217
OzempicSemaglutide88$109,405
XifaxanRifaximin97$76,539
XareltoRivaroxaban224$64,357
FarxigaDapagliflozin Propanediol189$55,687
JanuviaSitagliptin Phosphate178$50,203
Invega SustennaPaliperidone Palmitate12$37,912
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$32,147
PrezcobixDarunavir/Cobicistat12$31,226
ActemraTocilizumab18$29,799
JardianceEmpagliflozin115$29,645
DescovyEmtricitabine/Tenofov Alafenam12$27,951
Risperidone ErRisperidone Microspheres23$26,312
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog86$17,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$33$188,50424 claims
PfizerEliquis$43$172,217873 claims
Johnson & JohnsonXarelto, Invega Sustenna, Prezcobix$18$133,495248 claims
Novo NordiskOzempic$37$109,40588 claims
MerckJanuvia$18$50,203178 claims
NovartisEntresto$15$15,546118 claims
AbbVieLinzess$72$7,38913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Fountainville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →